CD274 and hepatocellular carcinoma: Since then, however, multiple new drugs (tyrosine kinase inhibitors (TKIs), anti-programmed death-1 (PD-1) (e.g., nivolumab), and anti-PD-L1 therapies (e.g., atezolizumab)), and their combinations, have been approved for first- and second-line therapy for advanced HCC [7,8,9,10,11,12,13].